THE MCMANUS GROUP for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access and reimbursement for Part B and Part D drugs. Advocating for access to biosimilars. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act H.R.2880 - Protecting Patients Against PBM Abuses Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | LD, Rep. Jon Porter |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R. 5378: Lower Costs, More Transparency Act, S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.1375/H.R.830 - HELP Copays Act. Issues related to PBM Delinking, including House: DRUG ACT HR 6283, S. 1542.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.